

## **Astellas Assesses the Impact of the Tohoku Earthquake**

**Tokyo, March 15, 2011** – Astellas Pharma Inc. (“Astellas”, TSE: 4503) is currently assessing the impact of the Tohoku Earthquake upon its various facilities and provides details of current conditions at these facilities below. At the same time Astellas expresses its deepest sympathy for those who have lost their lives and been displaced by the Tohoku Earthquake, which devastated the region on Friday, March 11, 2011. Astellas looks forward to a quick recovery from this natural calamity and offers its support in the relief efforts.

- **Regarding Astellas’ Employees**  
Astellas has confirmed that all of its and its affiliates’ employees are safe.
- **Facilities in Devastated Regions**
  - Manufacturing Facilities:  
Nishine Plant (Astellas Tokai Co., Ltd, Nishine, Hachimantai-shi, Iwate prefecture, “Nishine Plant”)  
Takahagi Plant (Astellas Pharma Chemicals Co., Ltd., Akahama, Takahagi-shi, Ibaraki prefecture, “Takahagi Plant”)
  - Research Facilities:  
Process Chemistry Labs. (Akahama, Takahagi-shi, Ibaraki prefecture)  
Tsukuba Research Center (Miyukigaoka) (Miyukigaoka, Tsukuba-shi, Ibaraki prefecture)  
Tsukuba Research Center (Tokodai) (Tokodai, Tsukuba-shi, Ibaraki prefecture)
- **Conditions of Facilities in Devastated Regions**
  - Manufacturing Facilities:  
Operations at both the Nishine and Takahagi Plants have been halted. Efforts to resume operation at the Nishine Plant have begun.  
At the Takahagi Plant, Astellas will continue to assess conditions of its manufacturing facilities so that it can resume operation as soon as possible, while maintaining its top priority of securing the safety of its employees.
  - Research Facilities:  
Process Chemistry Labs. (Takahagi) has currently halted operations. Astellas will continue to assess conditions of its research facilities so that it can resume operation as soon as possible, while maintaining its top priority of securing the safety of its employees.  
Efforts necessary to resume operations at the Tsukuba Research Center (Miyukigaoka) have already begun.  
There were no disruptions to essential utilities at the Tsukuba Research Center (Tokodai), and efforts to resume operations there have already begun.
- **Marketing Activities**  
Employees working at branch offices and marketing offices in the devastated regions have been instructed to remain on standby at home with maintaining its top priority of securing the safety of its employees.
- **Supplies of Products**  
While there are some differences by unit Astellas has more than 3 months of inventories of its mainstay products.



## Press Release

- **Impact Upon Earnings**

Astellas is currently assessing the impact of the earthquake upon its earnings and will quickly disclose pertinent information should it discover that its earnings are likely to be significantly impacted.

**About Astellas Pharma Inc.**

Astellas Pharma Inc., located in Tokyo, Japan, is a global pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas has approximately 16,000 employees worldwide. The organization is committed to becoming a global category leader in urology, immunology and infectious diseases, neuroscience, DM complications and metabolic diseases and oncology. For more information on Astellas Pharma Inc., please visit our website at <http://www.astellas.com/en>.

Contacts for inquiries or additional information:

Astellas Pharma Inc.(Japan)  
Corporate Communications  
Tel: +81-3-3244-3201  
Fax: +81-3-5201-7473  
<http://www.astellas.com/en>